

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Chemical product name : Buparvaquone Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : 1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS classification of chemical product**

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.  
H360D May damage the unborn child.  
H410 Very toxic to aquatic life with long lasting effects.

## Precautionary statements

:

**Prevention:**

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P261 Avoid breathing mist or vapours.  
P264 Wash skin thoroughly after handling.  
P271 Use only outdoors or in a well-ventilated area.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
N-Methyl-2-pyrrolidone	872-50-4	50	5-113

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

Buparvaquone	88426-33-9	$\geq 2.5 - < 10$	-
--------------	------------	-------------------	---

## 4. FIRST AID MEASURES

- |   |  |
|---|--|
| General advice  | : In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.   |
| If inhaled  | : If inhaled, remove to fresh air.<br>Get medical attention.   |
| In case of skin contact                                     | : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact                                      | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention.   |
| If swallowed  | : If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.  |
| Most important symptoms and effects, both acute and delayed | : Causes skin irritation.<br>Causes serious eye irritation.<br>May cause respiratory irritation.<br>May damage the unborn child.   |
| Protection of first-aiders                                  | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : Treat symptomatically and supportively.  |

## 5. FIREFIGHTING MEASURES

- |                                       |   |
|---------------------------------------|---|
| Suitable extinguishing media          | : Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media        | : None known.   |
| Specific hazards during fire-fighting | : Exposure to combustion products may be a hazard to health.  |
| Hazardous combustion products         | : Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )   |
| Specific extinguishing methods        | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers. |

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
7.0	2025/04/14	2091131-00017	2024/09/28
			Date of first issue: 2017/10/17

---

Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.  
for firefighters Use personal protective equipment.

---

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**7. HANDLING AND STORAGE****Handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Avoid breathing mist or vapours.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

Keep container tightly closed.  
 Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
 Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents  
 Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Keep tightly closed.  
 Keep in a cool, well-ventilated place.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	OEL-M	1 ppm 4 mg/m <sup>3</sup>	JP OEL JSOH
Further information: Skin absorption				
Buparvaquone	88426-33-9	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

**Biological occupational exposure limits**

Components	CAS-No.	Target substance	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-	Urine	End of shift (As)	100 mg/l	ACGIH BEI

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
7.0	2025/04/14	2091131-00017	2024/09/28
			Date of first issue: 2017/10/17

		pyrrolidone		soon as possible after exposure ceases)		
--	--	-------------	--	---	--	--

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.  
Impermeable protective gloves

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state : liquid

Colour : clear, red

Odour : No data available

Odour Threshold : No data available

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

Melting point/freezing point	:	No data available
Boiling point, initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Lower explosion limit and upper explosion limit / flammability limit	:	
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Evaporation rate	:	No data available
Auto-ignition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	No data available
Density and / or relative density	:	
Relative density	:	1 (20 °C)
Density	:	No data available
Relative vapour density	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics	:	
Particle size	:	Not applicable

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Acute oral toxicity	:	LD50 (Rat): 4,150 mg/kg Method: OECD Test Guideline 401 Remarks: The test was conducted equivalent or similar to guideline
Acute inhalation toxicity	:	LC50 (Rat): > 5.1 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403 Remarks: The test was conducted according to guideline
Acute dermal toxicity	:	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 402 Remarks: The test was conducted equivalent or similar to guideline

**Buparvaquone:**

Acute oral toxicity	:	LD50 (Rat): > 8,000 mg/kg  LD50 (Mouse): > 50 mg/kg Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	:	LD50: 2.5 mg/kg Application Route: Intravenous



**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	Skin irritation
Remarks	:	The test was conducted equivalent or similar to guideline

**Buparvaquone:**

Species	:	Mouse
Result	:	Mild skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405
Remarks	:	The test was conducted equivalent or similar to guideline

**Buparvaquone:**

Result	:	Mild eye irritation
--------	---	---------------------

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: The test was conducted according to guideline  Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: The test was conducted according to guideline  Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Method: OECD Test Guideline 482 Result: negative Remarks: The test was conducted equivalent or similar to guideline
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 474 Result: negative Remarks: The test was conducted according to guideline

**Carcinogenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Method	: OECD Test Guideline 451
Result	: negative
Remarks	: The test was conducted according to guideline
Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: negative
Remarks	: The test was conducted equivalent or similar to guideline

**Reproductive toxicity**

May damage the unborn child.

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

**Components:****N-Methyl-2-pyrrolidone:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative Remarks: The test was conducted according to guideline
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: positive Remarks: The test was conducted according to guideline
	Test Type: Fertility/early embryonic development Species: Rat Application Route: inhalation (vapour) Method: OECD Test Guideline 414 Result: positive Remarks: The test was conducted equivalent or similar to guideline
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Ingestion Method: OECD Test Guideline 414 Result: positive Remarks: The test was conducted equivalent or similar to guideline
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

May cause respiratory irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Assessment	: May cause respiratory irritation.
------------	-------------------------------------

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

Species	: Rat, male
NOAEL	: 169 mg/kg
LOAEL	: 433 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Method	: OECD Test Guideline 408
Remarks	: The test was conducted according to guideline

Species	: Rat
NOAEL	: 0.5 mg/l
LOAEL	: 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 96 Days
Method	: OECD Test Guideline 413
Remarks	: The test was conducted according to guideline

Species	: Rabbit, male
NOAEL	: 826 mg/kg
LOAEL	: 1,653 mg/kg
Application Route	: Skin contact
Exposure time	: 20 Days
Method	: OECD Test Guideline 410
Remarks	: The test was conducted equivalent or similar to guideline

**Buparvaquone:**

Species	: Cat
NOAEL	: 10 mg/kg
Application Route	: Intramuscular
Exposure time	: 5 d
Remarks	: No significant adverse effects were reported

NOAEL	: 5 mg/kg
Application Route	: Intravenous
Exposure time	: 4 d
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 6 d
Remarks	: No significant adverse effects were reported

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****N-Methyl-2-pyrrolidone:**

Skin contact	: Symptoms: Skin irritation
--------------	-----------------------------

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
7.0	2025/04/14	2091131-00017	2024/09/28
			Date of first issue: 2017/10/17

## 12. ECOLOGICAL INFORMATION

## Ecotoxicity

Components:**N-Methyl-2-pyrrolidone:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l Exposure time: 24 h Method: DIN 38412 Remarks: The test was conducted according to guideline
Toxicity to algae/aquatic plants	: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l Exposure time: 72 h  EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l Exposure time: 72 h
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 12.5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: The test was conducted according to guideline
Toxicity to microorganisms	: EC50 (activated sludge): > 600 mg/l Exposure time: 30 min Method: ISO 8192 Remarks: The test was conducted according to guideline

**Buparvaquone:**

Toxicity to fish	: LC50 (Brachydanio rerio (zebrafish)): 0.484 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.013 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Acute aquatic toxicity)	: 10
M-Factor (Chronic aquatic toxicity)	: 10

## Persistence and degradability

Components:**N-Methyl-2-pyrrolidone:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 73 %
------------------	--

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

Exposure time: 28 d  
Method: OECD Test Guideline 301C  
Remarks: The test was conducted according to guideline

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46  
Method: OECD Test Guideline 107  
Remarks: The test was conducted according to guideline

**Buparvaquone:**

Partition coefficient: n-octanol/water : log Pow: 6.5

**Mobility in soil**

No data available

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

(Buparvaquone)

Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964
Packing instruction (passenger aircraft)	: 964
Environmentally hazardous	: yes

**IMDG-Code**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.

(Buparvaquone)

Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

<b>ERG Code</b>	: 171
-----------------	-------

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Priority Assessment Chemical Substance

Chemical name	Number
N-Methyl-2-pyrrolidone	136

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
N-Methyl-2-pyrrolidone	$\geq 50$ - $< 60$	-

**Substances Subject to be Indicated Names**

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
N-Methyl-2-pyrrolidone	-

**Skin and Eye Damage Substances (ISHL MO Art. 594-2)**

Chemical name
N-methyl-2-pyrrolidone

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

**Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

**Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

**Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

**Poisonous and Deleterious Substances Control Law**

Not applicable

**Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof****Class I Designated Chemical Substances**

Chemical name	Administration number	Concentration (%)
N-Methyl-2-pyrrolidone	746	50



**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

**High Pressure Gas Safety Act**

Not applicable

**Explosive Control Law**

Not applicable

**Vessel Safety Law**

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

**Aviation Law**

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Noxious liquid substance(Category Y)

Pack transportation : Classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION**

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	2091131-00017	Date of first issue: 2017/10/17

---

JP OEL JSOH : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits

JP OEL JSOH / OEL-M : Occupational Exposure Limit-Mean

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN